BlossomHill Oncology Drug Targeted EGFR C797S Mutation

BlossomHill Therapeutics presented encouraging efficacy data from its Phase 1/2 SOLARA trial, demonstrating a 45% objective response rate from BH-30643 in EGFR C797S-positive NSCLC patients who developed resistance to prior treatments. The trial further confirmed a favorable safety profile and the company secured FDA Fast Track designation for the therapy, highlighting its significance for difficult-to-treat patients.